title: [Postoperative anterior chamber inflammation after posterior chamber intraocular lens implantation concurrent with pars plana vitrectomy and lensectomy].
abstract: The authors compared postoperative anterior chamber inflammation of triple procedure; diabetic pars plana vitrectomy, lensectomy with anterior capsule left intact and posterior chamber intraocular lens implantation anterior to anterior capsule, to those of various cataract surgeries with posterior chamber intraocular lens implantation and vitrectomies in diabetic retinopathy eyes. The inflammation was evaluated in terms of the incidence of inflammatory complications (fibrin reaction and posterior synechia of iris), and by periodical measurement of flare counts for postoperative 6 months using a laser flare-cell meter. The inflammation was more intense than those after the following 3 surgeries; phacoemulsification and in the bag intraocular lens implantation after continuous curvilinear capsulorhexis, extracapsular extraction and in the bag intraocular lens implantation after can opener capsulotomy, and vitrectomy alone. The inflammation, however, was less intense compared with that of another method of triple procedure; pars plana vitrectomy, phacoemulsification and in the bag intraocular lens implantation after continuous curvilinear capsulorhexis or can opener capsulotomy, and development of posterior synechia was rarely observed.
authors.affiliation: Department of Ophthalmology, Aichi Medical University, Japan.
authors.forename: G
authors.initials: G
authors.lastname: Ariki
authors.forename: N
authors.initials: N
authors.lastname: Ogino
mesh_terms: D000328:Adult; D000368:Aged; D000867:Anterior Chamber; D003930:Diabetic Retinopathy / Q000601:surgery; D005128:Eye Diseases / Q000209:etiology; D005260:Female; D006801:Humans; D007249:Inflammation / Q000209:etiology; D007908:Lens, Crystalline / Q000601:surgery*; D007910:Lenses, Intraocular; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000209:etiology*; D014821:Vitrectomy / Q000009:adverse effects*